Viable strategies to facilitate liver transplantation for human immunodeficiency virus coinfection.
Stock
Peter G
PG
Fung
John
J
D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000401:mortality / Q000601:surgery / Q000821:virology; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000401:mortality / Q000821:virology; D015497:HIV-1 / Q000472:pathogenicity*; D006305:Health Status Indicators; D006509:Hepatitis B / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D006526:Hepatitis C / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000401:mortality / Q000601:surgery / Q000821:virology; D017093:Liver Failure / Q000175:diagnosis* / Q000401:mortality / Q000601:surgery / Q000821:virology; D008113:Liver Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000601:surgery / Q000821:virology; D016031:Liver Transplantation / Q000009:adverse effects / Q000401:mortality; D008954:Models, Biological; D018579:Patient Selection; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D014850:Waiting Lists
D000998:Antiviral Agents